GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...

Halozyme Therapeutics (HALO) shares edged 0.5% higher Wednesday morning after it raised its financial outlook and announced ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...

WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic ...

Halozyme Therapeutics (NASDAQ:HALO) used an investor conference call to outline a series of strategic and financial updates, ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug ...

Professor Lisa Volpatti developed a targeted approach that directs anti-inflammatory proteins to diseased arteries, reducing ...

A new study led by the University of Miami Miller School of Medicine's Kirill Martemyanov, Ph.D., and international ...

Dermatology is entering a "biological revolution," with engineered tissues and bio-machines offering new therapeutic ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...

Doron Therapeutics, a clinical-stage biotechnology company developing novel biologics for musculoskeletal diseases, today announced that the initial patients have been dosed in its Phase 3 clinical ...

The Surf Bio acquisition comes shortly after Halozyme bought another company with a subcutaneous delivery technology, ...